New sedative could help ventilator patients breathe easier

NCT ID NCT07596589

Recruiting now Disease control Sponsor: Southeast University, China Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether remimazolam, a newer sedative, can improve outcomes for ICU patients who need a breathing tube and sedation. Researchers will compare remimazolam to standard sedatives in 80 adults. The main goal is to see if patients spend more days free from the ventilator, with fewer side effects like confusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: remimazolam
What this could lead to: If successful, remimazolam could become a safer sedation option for ICU patients on ventilators, potentially reducing time on the ventilator and complications like delirium.
What could go wrong: This is a small, single-center pilot study with only 80 participants, so results may not apply broadly. The drug may not prove better than current sedatives, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MECHANICALLY VENTILATED ICU PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MECHANICALLY VENTILATED ICU PATIENTS REMIMAZOLAM BESYLATE SEDATION

Contacts and locations

Locations

Zhongda Hospital
RECRUITING

Nanjing, Jiangsu, 210009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.